BioSight
Companies
Zentalis Pharmaceuticals, Inc. logo

ZNTL

NASDAQSAN DIEGO, CA
Zentalis Pharmaceuticals, Inc.

Zentalis is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a small-molecule drug candidate that Zentalis aims to position as first-in-class and best-in-class. Zentalis is currently running Phase 3 clinical trials of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer, with plans to generate data from ongoing studies.

Price history not yet available for ZNTL.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar